No­vo Nordisk ad­dress­es off-la­bel Ozem­pic use as it grap­ples with mul­ti­ple short­ages

On the heels of We­govy sup­ply trou­bles, No­vo Nordisk is re­port­ing a short­age of its di­a­betes treat­ment Ozem­pic which con­tains the same ac­tive in­gre­di­ent, semaglu­tide.

The com­pa­ny told End­points News in an email last week that it’s ex­pe­ri­enc­ing “in­ter­mit­tent sup­ply dis­rup­tions” for the Ozem­pic pen that de­liv­ers 0.25 and 0.5 mg dos­es of the drug, caused by “in­cred­i­ble de­mand cou­pled with over­all glob­al sup­ply con­straints.” On Dec. 7, the Amer­i­can So­ci­ety of Health-Sys­tem Phar­ma­cists re­port­ed short­ages af­fect­ing both the 0.25 mg or 5 mg dos­es, as well as the 1 mg and 2 mg dos­es us­ing var­i­ous pen in­jec­tors.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER